Galenica

Pharmaceuticals
GALE.SW
CHF 71 (0.84)%
Share price
$ 3.5 bn
Market Cap
$ 4.1 bn
Enterprise Value

Carbon footprint

1.9 Ton
GHG emissions per $ 1 mln investment
0.07x the weighted average for S&P 500
FY2021
How is this calculated?
+22%
YOY change in GHG emissions
Weaker than the -8.7% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

-6.2%
Proj. YOY change in GHG emissions (all Scopes)
In line with the -6.9% weighted average for S&P 500
FY2022
How is this calculated?

Galenica aims to reduce all Scopes by 25% by 2025 from a base year 2021


This target has not been verified as science based according to SBTi
Galenica's actual and proj. GHG emissions (all Scopes) (Kt of CO2e)

GHG emissions and Carbon intensity

Galenica's GHG emissions (location-based) (Kt of CO2e)
Galenica's Carbon intensity (Tons per 1 USDm)

Galenica's carbon footprint

Galenica reported Total CO2e Emissions - Location-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 7.7 Kt (+1.4/+22% y-o-y). Carbon intensity also surged to 1.7 t (+0.2/+13% y-o-y).

Galenica's Scope 3 emissions grew to 4.4 Kt (+0.14/+3.2% y-o-y). The growth rate declined vs. the previous periods (CAGR +7.6% since 4Q'17).

The company is committed to reducing all Scopes by 25% by 2025 from a base year 2021, which translates into the estimated reduction of -0.76 Kt per annum over the period of FY2022 - FY2025. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Company environmental metrics

Show more...
Copyright © 2022 Exerica. All rights reserved.